Trevi Therapeutics

NMQ:TRVI · US89532M1018

PharmaceuticalsSmall

360° View

Value40

Price/Sales—

Price/Earnings95

Price/Book5

Dividend Yield1

Growth88

Revenue Growth—

Profit Growth43

Capital Growth100

TSR 52w82

Safety85

Leverage91

Liquidity30

Refinancing68

Combined89

Sentiment87

Analyst Opinions78

Pro Holdings75

Opinion Changes14

Market Pulse97

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2011

Employees34

Websitetrevitherapeutics.com

ISINUS89532M1018

Last UpdateApr 2, 2026

Index & Theme

Chronic DiseasesPulmonologyRespiratoryPain ManagementHepatologyBiotechnologyHealth CarePharmaceutical

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonar…

Analysis

Trevi Therapeutics's 360° View rank of 96 places it among the strongest overall — better than 96% of its true peers.

It's a growth standout (88) and on the expensive side (40). On safety it is very well financed (85), and the market shows strongly positive sentiment (87). Taken together, its Combined rank of 89 reads as among the strongest overall.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Trevi Therapeutics with its peers

AnaptysBio

NSQ:ANAB

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Pliant Therapeutics

NSQ:PLRX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

ANI Pharma

NMQ:ANIP

CountryUSA

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

LENZ Therapeutics

NSQ:LENZ

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Structure Therapeutics

NMQ:GPCR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

MBX Biosciences

NSQ:MBX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →